HOLY SHIT SO UH SOMEONE FROM PFIZER (THE PHARMACEUTICAL COMPANY) LEFT THEIR BINDER AT THE BUS STOP AND THERE IS A LOT OF REALLY SENSITIVE INFORMATION IN THIS BINDER AND NO WAY TO TRACK THE REPRESENTATIVE THAT THIS BELONGS TO WHAT DO I DO????
There’s like birth certificates, visas, passports, marriage certificates, and a bunch of other stuff this is WILD
Betting that money is more persuasive than words, more employers vow to use financial rewards and penalties to prod their workers to fitness in 2012. Employers have seen serious problems related to obesity, she said, including higher rates of depression, absenteeism, low productivity and more medical claims. An overweight employee costs employers $5,000 more a year in health costs than a healthy-weight individual. The survey of 335 employers found that the share of companies that used financial rewards in health management programs increased to 54% in 2011 from 36% in 2009. In 2012, about 80% of companies plan to offer financial rewards.
“As I stare at an ink blot
Thinking why I think the thoughts I think
Paying 20 gs a year straight to my shrink
To analyze me on a couch
And while hes zoning out
Im tuning in to my inner child
So that explains why I get wild
On the weekend drinking no tomorrow
Sleep around to ease my sorrow
And it all relates to what happened in second grade
I am told there is a name for what is wrong inside my brain
And that fact alone makes me feel like Im hardly that insane
Ive undergone psychoanalysis
My dreams all full of phalluses
Psychotropics I imbibe
So happy to be prescribed
What I get from Pfizers not much different from Budweiser
In the end, you and I just fated to pretend”
Three leading senators are inquiring into drugmaker Pfizer Inc’s efforts to limit the sale of generic versions of its Lipitor cholesterol drug, which lost U.S. patent protection this week. Their concern was prompted by a newspaper report earlier this month that Pfizer had struck deals with leading insurers and pharmacy benefits managers, who negotiate prices on behalf of companies and insurers, to offer discounts on Lipitor if they block prescriptions for its generic versions
Pfizer To See Boosting Revenues On New Drugs Growth Through 2020
The company’s stock, expected to soar on
significant boost in revenues fuelled by new drugs growth in the coming
years, is bound to reap high returns for the investors in the long run;
Pfizer’s stock thus presents a perfect buying opportunity right now
Pfizer Inc. (PFE) the world’s largest drug manufacturer by sales
value, can generate higher long term revenues through the accelerated
growth of its new drugs, over the next five years. The new drugs
portfolio can’t come soon enough, because Pfizer’s financial results
paint a gloomy picture of the company’s performance.
giant has experienced a revenue decline since the fourth quarter of
2011, following the patent expiration of its top selling
cholesterol-fighting drug, Lipitor; at which point it became exposed to
generic competition. This was in December 2011. The company went on to
report a 7% year-over-year (YoY) decline in revenues, amounting to
$16.14 billion for the quarter.
The declining revenue trend has
been further exacerbated by the serial patent expiry of other
blockbuster drugs; the anti-inflammatory drug Celebrex in May 2014,
anti-bacterial Zyvox in November 2014.
Pfizer announced revenues
for the first quarter of 2015 of $10.9 billion, a decline of 3.8%
compared to revenues of $11.30 billion for the comparable quarter last
The company attributed revenue declines in the quarter to
lower Celebrex sales. Celebrex, which had generated almost 5.5% of the
company’s overall revenues last year, saw its sales dip by 67.15% YoY to
$205 million after the drug lost its US exclusivity last year.
is now looking to reverse the revenue decline to preserve its position
as the world’s largest pharmaceutical company by revenue. Key to this is
the success of new drugs, many with the potential to become a new
generation of blockbusters. This is Pfizer’s strategy to return it to
PFIZER’s NEW DRUGS PORTFOLIO
such drug is its cancer drug, Ibrance, soon expected to become the
company’s star blockbuster drug. Ibrance, got its green light from the
US Food and Drug Administration (FDA) in February this year. It has
pulled in sales of $38 million in the recent quarter, beating analysts’
expectations of $22 million. This drug, priced at $9850 for a month’s
dosage, and at $118,200 for a whole year’s course, has been estimated to
generate sales as high as $3.39 billion by 2018, holding massive
potential to lift the company out of its sales void.
Pfizer’s pipeline also seems strong enough to translate into a company success story.
pharma has almost 10 experimental drugs in Phase III stages with the
remaining 12 are in Phase II stages. Some of the would-be blockbusters
for the company, if approved, include generic versions of Johnson &
Johnson’s (JNJ) Remicade and Roche Holding Ltd.’s (ADR) (RHHBY)
Rituxan/MabThera and Herceptin.
Pfizer’s potential biosimilars
could generate a significant market share of the kind enjoyed by
brand-name drugs. Especially exciting in light of Remicade generating
sales of almost $6.65 billion in 2014 for J&J. Roche’s Herceptin
and Rituxan/MabThera pocketed sales of $6.90 billion and $7.54 billion,
respectively. The biosimilars market, expected to expand to $20
billion by 2020, holds massive potential for Pfizer if its three
biosimilars get their FDA approvals.
The company’s vaccine
business - currently contributing 9.9% towards Pfizer’s overall revenues
- is also expected to receive a massive boost. In February this year,
Pfizer acquired one of the world’s leading providers of injectables,
Hospira, Inc. (HSP) through a deal worth $16 billion. The worldwide
market value of the generic sterile injectable business is expected to
reach $70 billion by 2020; presenting a strong growth opportunity for
Another window of opportunity for the New York-based
pharmaceutical, is its increasing reach in the fast expanding
immunotherapy market. These drugs work by strengthening the body’s own
immune system in fighting cancers.
Pfizer’s breast cancer drug
Palbociclib —expected to win FDA approval in the near future — holds a
potential $4 billion in sales generated by 2020, estimated by JP Morgan
analysts. The company has been entering collaborations to further
enhance its focus on cancer; particularly immunotherapy cancer
treatments. One of the most recent relationships is its global
collaboration with BIND Therapeutics Inc (BIND) to develop and
commercialize such treatments.
The pharma has spent a considerable
sum of money on the research and development of new drugs. Its
R&D expenditure stood at $7.15 billion for fiscal 2014, marking an
increase of 9.14% YoY as compared to the R&D spend of $6.55 billion
in 2013. R&D spending for the recent quarter came at $1.88 billion, a
YoY increase of 16.3%. In the future, the R&D spending trend is
expected continue to grow in the same way.
drug sales stood at only $397 million in the recent quarter,
representing a total contribution of 3% towards the group’s overall
sales of $13.12 billion, reported by Bloomberg Intelligence analysts.
New drugs, on the back of the company’s recent development plans and its
enhanced focus on R&D, is expected to grow to a sizeable 17% by
2020, says Bloomberg Intelligence.
Drg 1: Pfizer’s new drugs portfolio could achieve annualized growth of
38.7% up to 2020, while the group sales annualized growth is expected to
stand at 0.2% up to 2020. Despite expected increases, in the impact of
new drugs, to 17% of PFE product offerings, revenues are still
projected to be flat.
Data compiled by Bloomberg Intelligence.
ACQSUITIONS AND COLLABORATIONS TO ADD TO FUTURE GROWTH
and prospective acquisitions and collaborations are also expected to
significantly boost the company’s growth over coming years.
word on the Street is that Pfizer is interested in buying Colorado-based
Clovis Oncology Inc (CLVS), which advance the growth of Pfizer’s
oncology portfolio given that Clovis’ two cancer drugs have already been
granted Breakthrough Therapy status and will be up for FDA approval by
next year. Clovis’ lung cancer drug Rociletinib was given the
Breakthrough Therapy designation for treating non-small lung cancer
(NSCLC) patients in May 2014. The company achieved the milestone when
its investigational ovarian cancer drug, Rucaparib, was granted the same
status only last month.
In addition, the Clovis’ strength in the
cancer drugs market will also be significantly enhanced by Pfizer’s
recent extension of its alliance with BIND Therapeutics. The two
companies signed an agreement, initially in April 2013, with a focus on
optimizing the therapeutic potential of Pfizer’s cancer drug pipeline.
The duo’s recent decision to further extend the collaboration for the
development and commercialization of Accurins, therapeutics developed
for the treatment of various cancers, came only last month. This
partnership is bound to strengthen Pfizer’s position in the expanding
cancer drugs market, already worth $100 billion in annual sales possibly
hitting $147 billion by 2018, according to a new report by the IMS
Institute for Healthcare Informatics, a unit of drug data provider IMS
Is Pfizer’s Financial Position Strong Enough To Support Growth Prospects?
has forecast it’s free cash flow to stand at $12.82 billion for 2015.
It therefore seems fully financially equipped to support increased
spending on R&D and make the acquisitions that can be accretive to
its pipeline. Pfizer’s cash flows are expected to increase to $15.29
billion for 2016 and to $22.49 billion in 2017. Once again, more than
enough for the company to invest in research and/or strategic
acquisitions even after making the required debt payments.
company’s total debt currently stands at $35.93 billion, out of which
Pfizer is liable to pay $3.7 billion of the total in 2016. The company
will be required to pay off almost $10.83 billion of its total debt over
the next three years, paying $3.76 billion in 2017, $2.32 billion in
2018 and $4.75 billion in 2019; leaving the company with ample cash for
other significant investments in R&D, accretive acquisitions and
PFIZER’S STOCK PERFORMANCE
stock price has gone up by 10.83% when analyzed for performance since
early May of last year. It’s stock has been underperforming when
compared to the NYSE ARCA Pharmaceutical Index (DRG), which has grown
15.60%, from May 2nd last year until May 1st of 2015. Pfizer shares
were also significantly below the S&P 500 Index, which has gained
13.14% in the same time frame.
Pfizer’s stock has been underperforming the market is made clear by the
comparison with the S&P 500 Index. This presents a good buying
opportunity, right now. The company’s stock, expected to soar with a
significant boost in revenue fuelled by new drugs growth in the coming
years, is bound to reap high returns for investors in the long run.
Thór in the Pfizer Fantasia show at Equine Affaire, November 2013 with the Silver Maple Show Team. We rode to the spooky sounds of Imogen Heap, the show was sold out, and the horses had as much fun as the riders!
Viagra now has another purpose besides giving erections.
Viagra’s most famous for giving people with erectile dysfunction a solution, but they discovered that aspect of how it works by accident while trying to make a high blood pressure drug. Now, it appears that drugs like Viagra can be used for something else that’s not quite so specific: preventing malaria. This is honestly something the world…
I heard that 23andMe is doing research for those with IBD (how genetics plays a role in IBD). Normally they charge $99 for their at home saliva kit (they send the kit to you, you send it back once you’ve swabbed your saliva) which determines your geographical heritage through your DNA. But if you’ve been diagnosed with IBD you can receive their kit for FREE, and they take your results and use it for their research on IBD, in which they’ve partnered with Pfizer.
Shire Has Outperformed AstraZeneca After Acquisition Bids For Both Failed To Materialize
Shire has outperformed AstraZeneca in terms of share price and earnings estimate increases after acquisition bids for both the companies failed last year
In 2014, the pharmaceutical sector saw two potential mega mergers fail, as a result of new tax rules enacted to sharply limit tax inversion arrangements which have become rampant in the US. A’ tax inversion’ simply means relocating the company HQ to a jurisdiction with lower corporation taxes. It can also include a merger or acquisition deal to allow the company to move its HQ, for example to Ireland or the UK.
The two deals were the $54.8 billion acquisition agreement between AbbVie Inc. (ABBV) and Shire Plc (SHPG). This broke off when AbbVie walked away from the table. As did Pfizer Inc.’s (PFE) £69 billion ($116.04 billion) bid for AstraZeneca Plc ADR (AZN) which was never accepted by AstraZeneca.
The AbbVie-Shire buy-up broke off even after both companies reached an acquisition agreement. AbbVie ended up paying a sizeable breakup fee. On the other hand, the proposed Pfizer-AstraZeneca merger never materialized as AstraZeneca remained committed to its stand-alone strategy.
Despite the fact that Shire was willing to be bought, ready to be acquired while AstraZeneca was confident about its stand-alone strategy, it turns out Shire has outperformed AstraZeneca in terms of share price and earnings estimate increases after the buy-ups failed, according to Bloomberg data.
Shire’s performance since AbbVie walked away from the deal
AbbVie made its first attempt on Shire on May 5th, 2014. The company went on to be snubbed by Shire a further three times before June 20th, 2014, when AbbVie went public with its offer to acquire Shire. Shire agreed to come to join talks for the fourth proposal, put forward on July 14th, 2014, the companies entering a definite acquisition agreement on July 18th, 2014. The terms of the agreement mandated AbbVie to relocate its headquarters to the UK, which would allow the combined company to reduce its tax liability to 13% in 2016 from 22% in 2014.
However, the US government went on to announce new tax regulations on September 14th, severely limiting the charm associated with tax inversion deals. AbbVie, as a result, abandoned plans to acquire Shire; scratching its agreement on October 20th, 2014 and paying $1.6 billion to Shire as a breakup fee. Shire’s stock price dropped by almost 30% when it became clear AbbVie had broken off the acquisition.
Afterward, Shire stock gained momentum as evident can be seen by the fact the company’s price has risen (up to yesterday) 42.17% at $254.71 when compared to the share price of $179.15 on October 20th, the day AbbVie broke off the buy up.
Shire’s shares have been outperforming the NASDAQ iShares Biotechnology Index (IBB), up 35.77%, as well as AbbVie, which has since gained 23%, from October 20th until yesterday’s close. Shire has been successful as a stand-alone entity.
Indeed, it has marked some major milestones since the end of the affair.
Currently, Shire has the highest consensus rating in the Stoxx 600 Healthcare Index. Goldman Sachs now believes the company is attractive as both a stand-alone company and as a takeover target by a larger pharmaceutical company.
In January, Shire agreed to buy NPS Pharmaceuticals, Inc. (NPSP) for $5.2 billion. Shire said that it expected the acquisition to be accretive to its adjusted earnings from next year onwards, leading to cost savings of approximately 25% to 35% of consensus forecasts.
The NPS acquisition started bringing in positive news for Shire when the Food and Drug Administration granted approval to Natpara, a blood calcium controlling drug developed by NPS. This drug is expected to bring in $542 million in sales for Shire, which will be accretive to the company’s growth.
During February, the company secured an approval from the FDA for the extended use of Vyvanse, its blockbuster drug designed to treat binge-eating disorder. This is estimated to affect about 2.8 million people in the US. Vyvanse is the first ever treatment option for this condition and is expected to generate sales of up to $300 million from the binge-eating disorder market.
Analysts have raised their estimate for Shire’s 2015 earnings by 6% since the deal was made official, compared to the sector average growth of -4.1%. Shire’s 2015 earnings estimates have increased by 0.73% as seen in the latest four-week analysts’ revisions to the company’s estimated 2015 earnings.
Shire is expected to report a 7.2% increase in earnings in 2015. The company is expected to report revenues of $6.37 billion for 2015, a 5.8% increase compared to the revenues for 2014.
AstraZeneca’s performance after it rejected acquisition bid from Pfizer
Pfizer showed its interest in acquiring AstraZeneca, placing its initial offer on January 5th, 2014. The company backed off from its planned buy out of AstraZeneca only after limited discussions clearly indicated AstraZeneca had no interest in selling the business.
Pfizer, despite AstraZeneca’s aggressive defenses, did extend its pursuit of the company from April 28th, 2014 onward — when the offer was first extended. It sweetened the offer twice until making its final offer of £69 billion ($116.04 billion) on May 18th, 2014. This was rejected by AstraZeneca the next day.
AstraZeneca reasoned that it was not interested in selling the business because feared Pfizer would spilt it into three different branches after the merger. These would be absorbed by different business units of Pfizer, thereby wiping away any chances of independent R&D activities by the company.
AstraZeneca has traded down by 1.9% since the May 19th, 2014 price of $70.64 when AstraZeneca rejected Pfizer’s advances. It is now valued at $69.74.
AstraZeneca, ever since rejecting Pfizer’s acquisition offer, has been underperforming the NYSE ARCA Pharmaceutical Index (DRG), which has since gained 16.05%. Its stock price has also trailed Pfizer’s stock, which has gained 16.69% from the day AstraZeneca rejected Pfizer’s offer right up to yesterday’s close.
Analysts estimate AstraZeneca’s earnings for 2015 have only risen by 2.1% since the offer was confirmed by Pfizer, against the sector average of -4.6%.
Since the first quarter of 2013, AstraZeneca has faced prolonged revenue decline as patents on its best selling drugs expire or near their expiration. The drugs mainly responsible for driving down company revenues include Crestor, Nexium and Seroquel. Seroquel lost its patent in 2012; the drug generated sales of $5.8 billion in 2011 before losing its patent. Sales are expected to fall to $559 million in 2017, an average annual decline of 27% each year. Crestor, set to lose its patents in 2016, raked in sales of $5.5 billion in 2014. Sales for this drug are expected to decline by 20%, on average, each year to $2.18 billion in 2017.
The company faced another setback when the FDA approved a generic version of Nexium, a drug which generated sales of $3.66 billion in 2014, developed by Teva Pharmaceutical Industries Ltd. (TEVA). The generic version of Nexium is expected to result in a sharp decline in sales generated by the branded drug, which lost its patents last year. Analysts expect Nexium’s sales to slide to $1.8 billion in 2017.
AstraZeneca, after rejecting Pfizer’s offer, joined hands with Eli Lilly and Co (LLY) to develop an investigational Alzheimer’s drug under a $500 million deal. The company also signed other deals with Pharmacyclics, Inc. (PCYC) and Johnson & Johnson (JNJ) to expand its reach in the cancer therapeutics segment.
AstraZeneca is expected to report revenues of $24.1 billion during 2015, marking a 7.7% decline when compared to 2014 revenues. AstraZeneca’s earnings per share are expected to decline by 0.9% YoY.
AstraZeneca was committed to its strategy of being a standalone firm; Shire was all ready to be merged into AbbVie. It turns out Shire has performed much better than AstraZeneca after the acquisition adventures came to an end for both companies.
Happy customers! Tasting absinthe this evening at The Great Food Event from 5:30-9pm! Join us along with tons of other #local #spirits #beer #food #desserts …and more! Visit us in the old Pfizer factory! #docsspirits #brooklyn #bedstuy #madeinbrooklyn #madeinNY #mixology #saturday #cocktails #brooklynspirits #buylocal #shoplocal (at Pfizer 630 Flushing Avenue Brooklyn)
Signs are going up, tables being prepped and we are working hard to turn the Pfizer Factory in Williamsburg into a bacon and booze playground for the senses. #Bacon #BaconPicnic #BaconLife #BaconLove #BaconFest #Food #FoodPorn #BaconPorn #Brooklyn #NYC #Delicious #FoodChat
The Trans-Pacific Partnership would create a super-treaty which would jeopardize the sovereignty of the nations involved by giving that power to large corporations like Wal-Mart, Monsanto, Goldman Sachs, Pfizer, Halliburton, Philip Morris, GE, GM, Apple.
There are currently 11 nations involved: U.S., New Zealand, Australia, Brunei, Chile, Malaysia, Peru, Singapore, Vietnam, Mexico and Canada. Japan has shown interest.
The economic power of this group is more than 40% larger than the 27- nation European Union.
TPP will offshore millions of good-paying jobs to low-wage nations, undercutting working conditions globally and increasing unemployment.
TPP will expand pharmaceutical monopoly protections and institute longer patents that will decrease access to affordable medications
TPP will limit food GMO labeling and allow the import of goods that do not meet US safe standards.
TPP will institute SOPA, PIPA, and CISPA-like regulations and Internet measures which restrict our right to free speech.
TPP will roll back Wall Street regulations, and prohibit bans on risky financial services.
TPP will give multinational corporations and private investors the right to sue nations in private tribunals. These tribunals have the power to overturn environmental, labor, or any other laws that limit profit, awarding taxpayer funded damages.
TPP will encourage the privatization of lands and natural resources in areas where indigenous people live.
This article is about Meet Our Scientists: “I need to believe in what my company is….
Meet Our Scientists: “I need to believe in what my company is doing,” says Vicki Cathcart, a Biosafety Officer in Groton Labs at Pfizer. “My first job out of college was working as a chemical engineer for a company that produced snack foods and it just wasn’t right for me. Even very early in my career, I knew…
I had this strange dream about murs the other night. I was at a murs show at a bar, there were only a few people there. He was wearing a leather jacket with a painting of the joker on it and had this huge afro, and in middle of the show he got a call saying he was getting sued by pfizer for talking about abusing xanax in his music. He storms off the stage and then everyone at the show ends up chilling with him on the basketball court outside the bar.
I dont even think murs talks about xanax in any of his music. I don’t even do xanax. Than I woke up and I found out that murs released a new album that day.